You are here

BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study

Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019 Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019
Friday, February 22, 2019 - 07:30